MRK News 57.25 04/21/2014 21:37:13 Merck & Company (MRK)
Post# of 273319
Posted On: 04/21/2014 10:37:15 PM
Merck & Company (MRK) 57.25 $MRK
Dow Climbs As Pharma Stocks Jump, but Will Drug M&A Hurt UnitedHealth?
Dan Caplinger, The Motley Fool - Motley Fool - 1 hr 33 mins ago
The Dow Jones Industrials rose more than 40 points Monday as investors continued to ride the wave of enthusiasm that has accompanied the beginning of earnings season. Leading the way higher for the Dow were Pfizer and Merck , which gained 2%...
Valeant to bid for Botox maker Allergan
By KEN SWEET and MATTHEW PERRONE - AP - 2 hrs 28 mins ago
NEW YORK (AP) — Valeant Pharmaceuticals has teamed up with activist investor Bill Ackman in a bid for Botox maker Allergan that could be worth about $40 billion.
Pfizer, Inc. Rebuffed: Is AstraZeneca plc Worth Another Try?
Stephen D., Simpson,, The Motley Fool - Motley Fool - Mon Apr 21, 5:30PM CDT
Big-time pharma mergers have had a mixed track record, with large combinations often leading to significant cost reductions (and firings) in sales and administration but at the cost of large disruptions to R&D. Pfizer is apparently not afraid...
Merck Rises 1.38% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Mon Apr 21, 4:03PM CDT
Merck (NYSE:MRK) traded in a range yesterday that spanned from a low of $56.40 to a high of $57.30. Yesterday, the shares gained 1.4%, which took the trading range above the 3-day high of $57.00 on volume of 6.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
After Yesterday's Rally of 1.38% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Mon Apr 21, 4:03PM CDT
Merck (NYSE:MRK) traded in a range yesterday that spanned from a low of $56.40 to a high of $57.30. Yesterday, the shares gained 1.4%, which took the trading range above the 3-day high of $57.00 on volume of 6.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Merck among NASA Cargo Launching to Space Station
PR Newswire - Mon Apr 21, 3:15PM CDT
When the SpaceX-3 cargo resupply mission launched to the International Space Station April 14, an experiment designed by Merck Research Laboratories of Kenilworth, N.J., was among the cargo headed to space.
Emerging 'Superbugs' -- and Why Investors Should Care
at The Street - Mon Apr 21, 11:23AM CDT
Antibiotic-resistant 'superbugs' are spreading, and drug companies and their investors should take notice.
Interesting May Stock Options For MRK
at The Street - Mon Apr 21, 11:08AM CDT
Consistently, one of the more popular stocks people enter into their stock options watchlist at Stock Options Channel is Merck & Co., Inc . So this week we highlight one interesting put contract, and one interesting call contract, from the May...
Pfizer, AstraZeneca Rise On Report Of Merger Talks
at Investor's Business Daily - Mon Apr 21, 10:13AM CDT
Big pharmas Pfizer (PFE) and AstraZeneca (AZN) were both up in early trading on the stock market today after word got out Sunday that Pfizer had offered $101 billion to buy its rival. Citing unnamed sources, the U.K.'s Sunday Times said that the two...
Johnson & Johnson's New Diabetes Drug: A Blockbuster in the Making?
Todd Campbell, The Motley Fool - Motley Fool - Mon Apr 21, 7:47AM CDT
The market for diabetes treatment has never been bigger, and that is propelling sales of Johnson & Johnson 's Invokana higher. According to data from Express Scripts , the nation spent 14% more on diabetes drugs in 2013 than it did in 2012....
3 Reasons the Market Is Down on Gilead Sciences
Brian Orelli, The Motley Fool - Motley Fool - Fri Apr 18, 5:30PM CDT
After a solid two-year run, Gilead Sciences has fallen from investors graces, down for the year. The biotech has become increasingly reliant on its hepatitis C drug Sovaldi, with competition from AbbVie and Merck around the corner. In the...
Jim Cramer: We're in the Grips of a Struggle
at The Street - Fri Apr 18, 12:51PM CDT
Companies that are inventing incredibly important drugs go down almost every day.
Biohazard? Gilead Leads 5 Big-Cap Biotech Earnings
at Investor's Business Daily - Fri Apr 18, 11:12AM CDT
Can biotech stocks bounce back? As recently as last month, the Medical-Biomed/Biotech group was ranked No. 1 out of IBD's 197 industries. But it's been dead last over the last four weeks, plunging 22.1%. That partly reflects growth stocks overall...
FDA Approves Merck's RAGWITEK(TM) (Short Ragweed Pollen Allergen Extract) Sublingual Tablet as Immunotherapy to Treat Short Ragweed Pollen-Induced Allergic Rhinitis with or without Conjunctivitis in Adults
Business Wire - Thu Apr 17, 5:22PM CDT
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved RAGWITEK(TM) (Short Ragweed Pollen Allergen Extract) Tablet for Sublingual Use (12 Amb a 1-U). RAGWITEK is an allergen extract indicated as immunotherapy for the treatment of short ragweed pollen-induced allergic rhinitis with or without conjunctivitis confirmed by positive skin test or in vitro testing for pollen-specific IgE antibodies for short ragweed pollen. RAGWITEK is approved for use in adults 18 through 65 years of age. RAGWITEK is not indicated for the immediate relief of allergic symptoms.
Has A Streamlined FDA Raised The Value Of Drug Stocks?
at Investor's Business Daily - Thu Apr 17, 4:33PM CDT
Last month, three Democrats from the U.S. Congress sent a now-famous letter to Gilead Sciences (GILD) questioning the $84,000 price of its new blockbuster hepatitis C medicine, Sovaldi. Among the reasons raising suspicions that the price didn't need...
FDA OKs Merck tablet to reduce ragweed allergies
By The Associated Press - AP - Thu Apr 17, 4:11PM CDT
WHITEHOUSE STATION, N.J. (AP) — U.S. regulators have again approved a Merck & Co. tablet for gradually reducing seasonal allergies, this time for ragweed pollen.
ALK announces FDA approval for Merck's ragweed sublingual allergy immunotherapy tablet RAGWITEK(r)
GlobeNewswire - Thu Apr 17, 2:13PM CDT
ALK (ALKB
C / OMX: ALK B / AKABY / AKBLF) today announced that the US Food and Drug Administration (FDA) has approved the Biologic License Application (BLA) for RAGWITEK.
Johnson & Johnson's 3 Major Strengths
Peter Stephens, The Motley Fool - Motley Fool - Thu Apr 17, 1:30PM CDT
I recently wrote a mini-series on Johnson & Johnson , where I focused on each of its three segments: pharmaceuticals, consumer goods, and medical devices. Now seems like an opportune moment to check out the strengths of J&J as a group, with...
If This Biotech Drops Much Further I'm Going to Buy It!
Sean Williams, The Motley Fool - Motley Fool - Thu Apr 17, 12:05PM CDT
We've seen a little bit of a relief rally over the past couple of days in the overall market with the start of earnings season giving investors hope that the U.S. economy and corporations can keep motoring higher. On the all, though, it's been a...
Merck Serono's President & CEO Belen Garijo has Been Appointed to Board of Directors of L'Oreal
PR Newswire Europe - Thu Apr 17, 11:39AM CDT
DARMSTADT, Germany and PARIS, April 17, 2014 /PRNewswire/ --
Dow Climbs As Pharma Stocks Jump, but Will Drug M&A Hurt UnitedHealth?
Dan Caplinger, The Motley Fool - Motley Fool - 1 hr 33 mins ago
The Dow Jones Industrials rose more than 40 points Monday as investors continued to ride the wave of enthusiasm that has accompanied the beginning of earnings season. Leading the way higher for the Dow were Pfizer and Merck , which gained 2%...
Valeant to bid for Botox maker Allergan
By KEN SWEET and MATTHEW PERRONE - AP - 2 hrs 28 mins ago
NEW YORK (AP) — Valeant Pharmaceuticals has teamed up with activist investor Bill Ackman in a bid for Botox maker Allergan that could be worth about $40 billion.
Pfizer, Inc. Rebuffed: Is AstraZeneca plc Worth Another Try?
Stephen D., Simpson,, The Motley Fool - Motley Fool - Mon Apr 21, 5:30PM CDT
Big-time pharma mergers have had a mixed track record, with large combinations often leading to significant cost reductions (and firings) in sales and administration but at the cost of large disruptions to R&D. Pfizer is apparently not afraid...
Merck Rises 1.38% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Mon Apr 21, 4:03PM CDT
Merck (NYSE:MRK) traded in a range yesterday that spanned from a low of $56.40 to a high of $57.30. Yesterday, the shares gained 1.4%, which took the trading range above the 3-day high of $57.00 on volume of 6.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
After Yesterday's Rally of 1.38% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Mon Apr 21, 4:03PM CDT
Merck (NYSE:MRK) traded in a range yesterday that spanned from a low of $56.40 to a high of $57.30. Yesterday, the shares gained 1.4%, which took the trading range above the 3-day high of $57.00 on volume of 6.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Merck among NASA Cargo Launching to Space Station
PR Newswire - Mon Apr 21, 3:15PM CDT
When the SpaceX-3 cargo resupply mission launched to the International Space Station April 14, an experiment designed by Merck Research Laboratories of Kenilworth, N.J., was among the cargo headed to space.
Emerging 'Superbugs' -- and Why Investors Should Care
at The Street - Mon Apr 21, 11:23AM CDT
Antibiotic-resistant 'superbugs' are spreading, and drug companies and their investors should take notice.
Interesting May Stock Options For MRK
at The Street - Mon Apr 21, 11:08AM CDT
Consistently, one of the more popular stocks people enter into their stock options watchlist at Stock Options Channel is Merck & Co., Inc . So this week we highlight one interesting put contract, and one interesting call contract, from the May...
Pfizer, AstraZeneca Rise On Report Of Merger Talks
at Investor's Business Daily - Mon Apr 21, 10:13AM CDT
Big pharmas Pfizer (PFE) and AstraZeneca (AZN) were both up in early trading on the stock market today after word got out Sunday that Pfizer had offered $101 billion to buy its rival. Citing unnamed sources, the U.K.'s Sunday Times said that the two...
Johnson & Johnson's New Diabetes Drug: A Blockbuster in the Making?
Todd Campbell, The Motley Fool - Motley Fool - Mon Apr 21, 7:47AM CDT
The market for diabetes treatment has never been bigger, and that is propelling sales of Johnson & Johnson 's Invokana higher. According to data from Express Scripts , the nation spent 14% more on diabetes drugs in 2013 than it did in 2012....
3 Reasons the Market Is Down on Gilead Sciences
Brian Orelli, The Motley Fool - Motley Fool - Fri Apr 18, 5:30PM CDT
After a solid two-year run, Gilead Sciences has fallen from investors graces, down for the year. The biotech has become increasingly reliant on its hepatitis C drug Sovaldi, with competition from AbbVie and Merck around the corner. In the...
Jim Cramer: We're in the Grips of a Struggle
at The Street - Fri Apr 18, 12:51PM CDT
Companies that are inventing incredibly important drugs go down almost every day.
Biohazard? Gilead Leads 5 Big-Cap Biotech Earnings
at Investor's Business Daily - Fri Apr 18, 11:12AM CDT
Can biotech stocks bounce back? As recently as last month, the Medical-Biomed/Biotech group was ranked No. 1 out of IBD's 197 industries. But it's been dead last over the last four weeks, plunging 22.1%. That partly reflects growth stocks overall...
FDA Approves Merck's RAGWITEK(TM) (Short Ragweed Pollen Allergen Extract) Sublingual Tablet as Immunotherapy to Treat Short Ragweed Pollen-Induced Allergic Rhinitis with or without Conjunctivitis in Adults
Business Wire - Thu Apr 17, 5:22PM CDT
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved RAGWITEK(TM) (Short Ragweed Pollen Allergen Extract) Tablet for Sublingual Use (12 Amb a 1-U). RAGWITEK is an allergen extract indicated as immunotherapy for the treatment of short ragweed pollen-induced allergic rhinitis with or without conjunctivitis confirmed by positive skin test or in vitro testing for pollen-specific IgE antibodies for short ragweed pollen. RAGWITEK is approved for use in adults 18 through 65 years of age. RAGWITEK is not indicated for the immediate relief of allergic symptoms.
Has A Streamlined FDA Raised The Value Of Drug Stocks?
at Investor's Business Daily - Thu Apr 17, 4:33PM CDT
Last month, three Democrats from the U.S. Congress sent a now-famous letter to Gilead Sciences (GILD) questioning the $84,000 price of its new blockbuster hepatitis C medicine, Sovaldi. Among the reasons raising suspicions that the price didn't need...
FDA OKs Merck tablet to reduce ragweed allergies
By The Associated Press - AP - Thu Apr 17, 4:11PM CDT
WHITEHOUSE STATION, N.J. (AP) — U.S. regulators have again approved a Merck & Co. tablet for gradually reducing seasonal allergies, this time for ragweed pollen.
ALK announces FDA approval for Merck's ragweed sublingual allergy immunotherapy tablet RAGWITEK(r)
GlobeNewswire - Thu Apr 17, 2:13PM CDT
ALK (ALKB
C / OMX: ALK B / AKABY / AKBLF) today announced that the US Food and Drug Administration (FDA) has approved the Biologic License Application (BLA) for RAGWITEK. Johnson & Johnson's 3 Major Strengths
Peter Stephens, The Motley Fool - Motley Fool - Thu Apr 17, 1:30PM CDT
I recently wrote a mini-series on Johnson & Johnson , where I focused on each of its three segments: pharmaceuticals, consumer goods, and medical devices. Now seems like an opportune moment to check out the strengths of J&J as a group, with...
If This Biotech Drops Much Further I'm Going to Buy It!
Sean Williams, The Motley Fool - Motley Fool - Thu Apr 17, 12:05PM CDT
We've seen a little bit of a relief rally over the past couple of days in the overall market with the start of earnings season giving investors hope that the U.S. economy and corporations can keep motoring higher. On the all, though, it's been a...
Merck Serono's President & CEO Belen Garijo has Been Appointed to Board of Directors of L'Oreal
PR Newswire Europe - Thu Apr 17, 11:39AM CDT
DARMSTADT, Germany and PARIS, April 17, 2014 /PRNewswire/ --
(0)
(0)